Table 3.
Summary of changes from baseline in HbA1c at week 26 in baseline HbA1c subgroups (LOCF)
| PBO | CANA 100 mg | CANA 300 mg | |
|---|---|---|---|
| Baseline HbA1c < 8.0%, n | 74 | 73 | 74 |
| Mean ± SD baseline (%) | 7.4 ± 0.3 | 7.3 ± 0.4 | 7.4 ± 0.3 |
| LS mean ± SE change | –0.02 ± 0.10 | –0.47 ± 0.09 | –0.67 ± 0.09 |
| Difference vs. PBO (95% CI) | –0.45 (–0.69, –0.21) | –0.64 (–0.88, –0.40) | |
| Baseline HbA1c ≥ 8.0% to < 9.0%, n | 48 | 51 | 49 |
| Mean ± SD baseline (%) | 8.4 ± 0.3 | 8.4 ± 0.3 | 8.4 ± 0.3 |
| LS mean ± SE change | –0.12 ± 0.12 | –1.02 ± 0.13 | –1.30 ± 0.12 |
| Difference vs. PBO (95% CI) | –0.90 (–1.21, –0.58) | –1.18 (–1.49, –0.87) | |
| Baseline HbA1c ≥ 9.0%, n | 28 | 31 | 29 |
| Mean ± SD baseline (%) | 9.5 ± 0.7 | 9.6 ± 0.4 | 9.6 ± 0.5 |
| LS mean ± SE change | –0.44 ± 0.22 | –1.55 ± 0.22 | –1.59 ± 0.24 |
| Difference vs. PBO (95% CI) | –1.11 (–1.68, –0.53) | –1.15 (–1.74, –0.56) |
LOCF, last observation carried forward; PBO, placebo; CANA, canagliflozin; SD, standard deviation; LS, least squares; SE, standard error; CI, confidence interval.